Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Nasal decongestants are widely used to relieve nasal congestion caused by conditions such as allergic rhinitis, sinusitis, and the common cold. These medications function by constricting nasal blood vessels, reducing swelling, and improving airflow. Despite their effectiveness, improper use can result in adverse effects, including rebound congestion and cardiovascular complications.

Materials And Methods: A cross-sectional study was conducted among 300 adult residents of Hail, Saudi Arabia, using a structured questionnaire. Participants were selected through simple random sampling. The questionnaire assessed the frequency of nasal decongestant use, types of decongestants preferred, reasons for use, and awareness regarding potential health risks. Data were analyzed using descriptive statistics, and Chi-square tests were performed to evaluate associations between demographic factors and decongestant use.

Results: Among the participants, 65% reported regular nasal decongestant use, with 45% preferring topical decongestants (e.g., oxymetazoline) and 55% using oral formulations (e.g., pseudoephedrine). The majority (72%) reported self-medicating without medical consultation, while 60% were unaware of the risk of rebound congestion. Individuals with a history of allergic rhinitis or sinusitis were significantly more likely to use nasal decongestants frequently ( < 0.05). Additionally, 30% of users experienced side effects, including increased heart rate (15%) and nasal irritation (10%).

Conclusion: The study highlights a high prevalence of nasal decongestant use in Hail, largely influenced by environmental factors and a lack of public awareness regarding potential risks. The findings underscore the need for targeted public health campaigns and pharmacist-led interventions to promote safer usage practices.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12244941PMC
http://dx.doi.org/10.4103/jpbs.jpbs_364_25DOI Listing

Publication Analysis

Top Keywords

nasal decongestants
12
nasal decongestant
12
nasal
9
prevalence nasal
8
allergic rhinitis
8
rhinitis sinusitis
8
effects including
8
rebound congestion
8
awareness potential
8
decongestants
5

Similar Publications

Purpose: Spinal anesthesia-induced hypotension can cause detrimental effects on both the mother and the fetus, and it remains a significant concern in obstetric anesthesia. The use of vasopressors is considered the most reliable and effective approach. Previous studies have shown that norepinephrine appears to be superior to phenylephrine in maintaining maternal heart rate and cardiac output.

View Article and Find Full Text PDF

Background: Topical oxymetazoline hydrochloride 0.1% is a pharmacologic agent for eyelid elevation.

Objective: This study investigates changes in eyelid position and patient-reported aesthetic outcomes following topical oxymetazoline.

View Article and Find Full Text PDF

Relevance: Acute rhinosinusitis is one of the most common ENT diseases. Topical complex nasal spray Polydexa with phenylephrine (PE), which includes an aminoglycoside antibiotic, is effective as a local therapy. There are no data on the toxic effects of Polydexa with PE in the medical literature.

View Article and Find Full Text PDF

Background: Nasal congestion, a common symptom of various upper respiratory conditions, is often treated with nasal decongestants, which are effective vasoconstrictors used to relieve blockage in conditions like allergic rhinitis, rhinosinusitis, and nasal polyps. However, frequent use of these decongestants can lead to both local and systemic side effects.

Methods: This cross-sectional study used an online, self-administered questionnaire to collect data from our population as regard on the inclusion and exclusion criteria.

View Article and Find Full Text PDF

Topical Ophthalmic Oxymetazoline: A Promising Treatment Option for Ocular Synkinesis.

Facial Plast Surg Aesthet Med

August 2025

Section of Facial Plastic and Reconstructive Surgery, Head and Neck Department, Cleveland Clinic, Cleveland, Ohio, USA.

To evaluate objective and subjective outcomes in patients with ocular synkinesis before and 1 month after daily ophthalmic oxymetazoline, using standardized photographs, the Sunnybrook Facial Grading Scale, and patient-reported measures. Ophthalmic oxymetazoline, an alpha-adrenergic agonist Food and Drug Administration approved for acquired blepharoptosis, stimulates eyelid retractors but has not been studied for ocular synkinesis. Adult outpatients with ocular synkinesis self-administered 0.

View Article and Find Full Text PDF